Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470313 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01470313 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT01470313, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in disease activity will also be evaluated.
Interventions
- DRUG Placebo
- DRUG PD-0360324
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01470313
The ClinicalTrials.gov registry entry for NCT01470313 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01470313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01470313 about?
NCT01470313 is a clinical study titled "A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus". This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in disease activity will also be evaluated.
What is the current status of trial NCT01470313?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01470313?
The interventions under investigation include: Placebo (DRUG), PD-0360324 (DRUG).
Who is sponsoring clinical trial NCT01470313?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.